Gene therapy company uniQure NV may have disappointed investors hoping it would be the latest M&A target, but analysts have generally applauded its decision to take a different path.
Last week saw it strike a $450m upfront licensing deal for lead candidate, the Phase III hemophilia B gene therapy EtranaDez (formerly AMT-061) to blood disorders specialist CSL Behring
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?